V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015309 | 160016113 | 0 | 80.1 | null | 2021-05-25 | 2021-06-06 | STS Rhabdomyosarcoma RMS 2005 VA | null | null | METHOTREXATE + VINBLASTINE | 101681748 |
| 160015339 | 160016115 | null | null | Curative (C) | 2018-12-13 | 2019-01-21 | Etoposide oral | 02 | N | RUCAPARIB | 100091203 |
| 160015341 | 160016116 | 1.57 | 94 | null | 2017-03-28 | 2017-07-24 | Etoposide oral | 01 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100707005 |
| 160015343 | 160016117 | 0 | 40.45 | 03 | 2019-06-11 | 2020-03-18 | IVA | N | N | STS NON-RHABDO EPSSG 2005 IFOS | 100568238 |
| 160015347 | 160016118 | 1.69 | 52 | Curative (C) | 2021-11-29 | 2021-12-10 | Doxorubicin + Ifosfamide | 02 | N | GEMCARBO | 101648287 |
| 160015363 | 160016119 | 0 | 89.3 | null | null | null | NB HRNBL-1 BUMEL MAT | 02 | null | TRIAL | 101490726 |
| 160015365 | 160016120 | 1.59 | 64.2 | null | 2021-12-11 | 2021-12-17 | CARBOPLATIN + LIPOSOMAL DOX | null | null | TRASTUZUMAB | 100493687 |
| 160015368 | 160016121 | 1.74 | 84 | null | 2020-05-24 | 2020-06-02 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | DACARBAZINE | 101455843 |
| 160015369 | 160016122 | null | 55.1 | Palliative (P) | 2020-06-26 | 2020-07-22 | EW EuroEwing 2012 Arm B IE | 01 | N | NOT MATCHED | 100636134 |
| 160015372 | 160016123 | 1.58 | 86.4 | Curative (C) | 2020-03-14 | 2020-04-10 | Olaparib | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101420929 |
| 160015378 | 160016124 | 1.75 | 86.7 | Curative (C) | 2018-07-27 | 2018-08-31 | Cyclophosphamide + Topotecan | 02 | N | TRIAL | 100356244 |
| 160015385 | 160016125 | 1.61 | 117.8 | Curative (C) | null | 2017-07-23 | WT SIOP 2002 01 post op Carbo, Etop | 02 | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100916339 |
| 160015392 | 160016126 | 1.89 | 98.4 | Neo-adjuvant (N) | 2017-11-30 | 2018-01-05 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | PEMBROLIZUMAB | 101583893 |
| 160015394 | 160016127 | 1.66 | 69 | Palliative (P) | 2019-09-23 | 2019-09-23 | null | 02 | N | IFOSFAMIDE | 101565022 |
| 160015408 | 160016128 | null | null | Curative (C) | 2019-12-13 | 2019-12-19 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | EW EUROEWING 2012 ARM A VAC | 100543165 |
| 160015412 | 160016129 | 1.59 | 66.4 | Curative (C) | 2017-09-23 | 2017-09-23 | FAKTION Trial | N | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100477131 |
| 160015420 | 160016130 | null | null | Palliative (P) | 2018-05-09 | 2018-05-15 | EW Rel Irinotecan & Temozolomide | N | N | IRINOTECAN + TEMOZOLOMIDE | 101071981 |
| 160015422 | 160016131 | 0 | 71 | null | 2016-01-19 | 2016-08-25 | DACARBAZINE + GEMCITABINE | null | null | OLARATUMAB | 100398937 |
| 160015424 | 160016132 | 0 | 26.7 | Palliative (P) | 2018-05-23 | 2019-06-03 | EW EuroEwing 2012 Arm B VC | 01 | N | PEMBROLIZUMAB | 101820357 |
| 160015437 | 160016134 | 0 | 77.8 | Palliative (P) | 2018-02-14 | 2018-03-19 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 101573225 |
| 160015442 | 160016135 | 1.78 | 11.2 | Palliative (P) | 2018-12-07 | 2018-12-18 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100059880 |
| 160015449 | 160016136 | 1.71 | 98.1 | Palliative (P) | null | null | Trial Unspecified | 02 | N | EW EUROEWING 2012 ARM B IE | 101614057 |
| 160015451 | 160016137 | 1.86 | 59.3 | Adjuvant (A) | 2017-12-28 | 2018-02-02 | CARBOPLATIN + GEMCITABINE | N | N | GEMCITABINE | 100134593 |
| 160015460 | 160016138 | 1.67 | 64.7 | Disease modification (D) | 2019-05-27 | 2019-05-27 | Cyclophosphamide oral | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100164828 |
| 160015471 | 160016140 | null | 73.3 | Curative (C) | 2019-03-21 | 2019-04-07 | Cyclophosphamide oral | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101462260 |
| 160015473 | 160016141 | 0 | 13.4 | Curative (C) | 2020-05-21 | 2020-05-31 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | TRIAL | 101665415 |
| 160015474 | 160016142 | 1.63 | 69.5 | Curative (C) | 2016-03-13 | 2016-03-13 | Rucaparib | 02 | N | GEMCITABINE | 100648484 |
| 160015478 | 160016143 | 1 | 75 | Palliative (P) | 2017-08-11 | 2017-11-21 | STS Non-Rhabdo EpSSG 2005 VA | 01 | N | NOT MATCHED | 101286188 |
| 160015493 | 160016144 | 1.65 | 59.3 | Palliative (P) | null | 2017-08-09 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | TRASTUZUMAB EMTANSINE | 100142276 |
| 160015494 | 160016145 | 0 | 14 | Neo-adjuvant (N) | 2017-09-06 | 2017-09-22 | Niraparib | 02 | N | IFOSFAMIDE | 101396070 |
| 160015504 | 160016146 | 1.59 | 73 | Curative (C) | 2019-01-03 | 2019-03-01 | Trial Unspecified | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101565723 |
| 160015508 | 160016147 | 1.76 | 78.5 | Neo-adjuvant (N) | 2020-08-02 | 2020-10-05 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101711066 |
| 160015513 | 160016148 | 1.71 | 99.1 | 03 | 2020-08-06 | 2020-08-06 | ETOP 13-18 BEAT-meso Trial | 02 | N | NB HRNBL-1 COJEC IND COURSE B | 101828378 |
| 160015519 | 160016149 | 0 | 57.5 | Curative (C) | 2019-08-23 | 2019-08-23 | null | 02 | null | FLUOROURACIL + OXALIPLATIN | 100116048 |
| 160015522 | 160016150 | 1.63 | 92 | null | 2020-04-16 | 2020-04-19 | NB Relapsed CCLG guidelines TVD | 02 | null | ICON8B TRIAL | 100243249 |
| 160015524 | 160016151 | 1.84 | 64.25 | Neo-adjuvant (N) | 2017-08-25 | 2017-10-06 | Dactinomycin + Vincristine | 02 | N | CYCLOPHOSPHAMIDE | 100170197 |
| 160015526 | 160016152 | 1.57 | 17.5 | Curative (C) | 2018-02-07 | 2018-03-21 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | null | GEMCITABINE | 100474742 |
| 160015528 | 160016153 | 0 | 35.1 | null | 2016-02-27 | 2016-06-03 | NB HRNBL-1 BUMEL MAT | 02 | null | NB HRNBL-1 COJEC IND COURSE C | 101653921 |
| 160015535 | 160016154 | null | null | Curative (C) | 2018-01-30 | 2018-01-30 | Niraparib | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101424685 |
| 160015536 | 160016155 | 0 | 92 | null | 2021-08-20 | 2021-08-30 | Dacarbazine | 02 | null | PEMBROLIZUMAB | 101364893 |
| 160015541 | 160016156 | 1.6 | 0 | Curative (C) | 2018-02-17 | 2018-02-22 | EW EuroEwing 2012 Arm B IE | 02 | N | NIRAPARIB | 100909480 |
| 160015545 | 160016157 | 1.83 | 74.7 | Palliative (P) | 2017-03-14 | 2017-03-16 | CVP R | 02 | N | CISPLATIN + ETOPOSIDE | 101403798 |
| 160015547 | 160016158 | 0 | 90 | null | 2018-11-27 | 2018-11-29 | PEMBROLIZUMAB | 02 | null | TRIAL | 101260596 |
| 160015548 | 160016159 | 0 | 59 | Neo-adjuvant (N) | 2019-08-06 | 2020-08-04 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | N | RUCAPARIB | 101738382 |
| 160015562 | 160016160 | 0 | 12 | Palliative (P) | null | 2019-10-18 | ATOMIC-MESO TRIAL | null | N | POMALIDOMIDE | 100083636 |
| 160015563 | 160016161 | 1.68 | 0 | Curative (C) | 2022-04-09 | 2022-04-25 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | EW EUROEWING 2012 ARM B VC | 100221532 |
| 160015570 | 160016162 | 0 | 98.6 | null | 2018-02-20 | 2018-03-13 | CARBOPLATIN + VINORELBINE | 02 | null | NEMO TRIAL | 100897573 |
| 160015591 | 160016163 | 1.82 | 68 | Curative (C) | 2017-08-29 | 2017-09-13 | GEMCITABINE | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 100232763 |
| 160015593 | 160016164 | 1.15 | 92.9 | Palliative (P) | 2018-06-26 | 2019-02-08 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | null | STS RHABDOMYOSARCOMA RELAPSE IRINOTECAN/ TEMOZOLOMIDE/ VINCRISTINE | 100812647 |
| 160015595 | 160016165 | null | 14.8 | null | 2018-03-20 | 2018-04-20 | GEMCITABINE | 02 | null | EW EUROEWING 2012 ARM B VC | 100668641 |